Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.

Lentz RW, Lang J, Pitts TM, Blatchford P, Hu J, Jordan KR, Van Bokhoven A, Bagby SM, Dominguez ATA, Binns CA, Robinson HR, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Lieu CH, Wadlow RC, Spencer K, Scott AJ, Boland PM, Hochster HS, Messersmith WA

Open source

DOI: 10.1158/2767-9764.crc-25-0332
Published: 2025 Nov 1
Container: Cancer research communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/2767-9764.crc-25-0332,
  title = {Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.},
  author = {Lentz RW and Lang J and Pitts TM and Blatchford P and Hu J and Jordan KR and Van Bokhoven A and Bagby SM and Dominguez ATA and Binns CA and Robinson HR and Balmaceda N and Baiyee E and Leal AD and Kim SS and Davis SL and Lieu CH and Wadlow RC and Spencer K and Scott AJ and Boland PM and Hochster HS and Messersmith WA},
  year = {2025},
  journal = {Cancer research communications},
  doi = {10.1158/2767-9764.crc-25-0332},
  url = {https://doi.org/10.1158/2767-9764.crc-25-0332}
}

RIS

TY  - JOUR
TI  - Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.
AU  - Lentz RW
AU  - Lang J
AU  - Pitts TM
AU  - Blatchford P
AU  - Hu J
AU  - Jordan KR
AU  - Van Bokhoven A
AU  - Bagby SM
AU  - Dominguez ATA
AU  - Binns CA
AU  - Robinson HR
AU  - Balmaceda N
AU  - Baiyee E
AU  - Leal AD
AU  - Kim SS
AU  - Davis SL
AU  - Lieu CH
AU  - Wadlow RC
AU  - Spencer K
AU  - Scott AJ
AU  - Boland PM
AU  - Hochster HS
AU  - Messersmith WA
PY  - 2025
JO  - Cancer research communications
DO  - 10.1158/2767-9764.crc-25-0332
UR  - https://doi.org/10.1158/2767-9764.crc-25-0332
ER  -

APA

RW, L., J, L., TM, P., P, B., J, H., KR, J., A, V. B., SM, B., ATA, D., CA, B., HR, R., N, B., E, B., AD, L., SS, K., SL, D., CH, L., RC, W., K, S., AJ, S., PM, B., HS, H., & WA, M. (2025). Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer.. Cancer research communications. https://doi.org/10.1158/2767-9764.crc-25-0332

Source records

pubmed · retrieved 2026-09-26T09:45:15.405Z